VITRAKVI▼ (larotrectinib) is available as an oral solution for both adults and children, and can be taken with or without food1
VITRAKVI capsules and oral solution may be used interchangeably1
- 100 mg and 25 mg capsules
- 20 mg/mL oral solution
In adults:
100 mg taken orally twice daily, until disease progression or until unacceptable toxicity1
Stock images. Not real patients. For illustrative purposes only.
Adapted from VITRAKVI Summary of Product Characteristics.
In children:
100 mg/m2 taken orally, twice daily with a maximum of 100 mg per dose until disease progression or until unacceptable toxicity occurs1
Stock images. Not real patients. For illustrative purposes only.
Adapted from VITRAKVI Summary of Product Characteristics.
VITRAKVI dose can be modified to help manage adverse events1
For all Grade 2 adverse reactions:
Continued dosing may be appropriate, though close monitoring to ensure no worsening of the toxicity is advised. Patients with Grade 2 ALT and/or AST increases should be followed with serial laboratory evaluations every 1–2 weeks after the observation of Grade 2 toxicity until resolved to establish whether a dose interruption or reduction is required.1
Grade 3 and 4 adverse reactions:1
VITRAKVI should be withheld until the adverse reaction resolves or improves to baseline or Grade 1. Resume at the next dose modification if resolution occurs within 4 weeks.
VITRAKVI should be permanently discontinued if a grade 3 and 4 adverse reaction does not resolve within 4 weeks.
Recommended dose modifications for VITRAKVI for adverse reactions1
|
Adult and paediatric patients with body surface area |
First dose modification |
|
of at least 1.0 m2 |
75 mg twice daily |
|
less than 1.0 m2 |
75 mg/m2 twice daily |
Second dose modification | |
50 mg twice daily | |
50 mg/m2 twice daily |
|
Third dose modification |
|
|
100 mg once daily |
|
|
25 mg/m2 twice daily |
Adapted from VITRAKVI Summary of Product Characteristics.
Adapted from VITRAKVI Summary of Product Characteristics.
REGISTER FOR E-COMMUNICATION
REGISTER FOR EVENTS
Reporting adverse events and quality complaints
Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigiliance. Reports can also be sent directly to Bayer via this link. Both side effects or quality complaints can be reported to Bayer by email to adr-ireland@bayerhealthcare.com
